CAMP4 THERAPEUTICS CORPORATION CAMP
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -35.40%
- 1 year
- -1.74%
- Open
- 3.86
- Prev close
- 3.90
- Mkt cap
- 248.50M
- Vol
- 138.00K
- Avg vol
- 264.01K
- EPS
- -2.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.78
- High
- 4.00
- Forward P/E
- -2.52
- Beta
- 0.00
- Short ratio
- 2.72
- Inst. own
- 42.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 8, 2024
- 50-d avg
- 8.46
- 200-d avg
- 8.46
- 1y target
- 19.91
News
2 days ago zacks.com
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
5 days ago benzinga.com
CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company…
5 days ago globenewswire.com
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
-
1 week ago benzinga.com
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
1 week ago marketbeat.com
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production…
-
2 weeks ago benzinga.com
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
2 weeks ago globenewswire.com
CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory…
1 month ago defenseworld.net
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages
CAMP4 Therapeutics Corporation (NASDAQ: CAMP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat…
-
1 month ago benzinga.com
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
1 month ago defenseworld.net
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Therapeutics (NASDAQ: CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results…
1 month ago seekingalpha.com
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
1 month ago marketbeat.com
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
-
1 month ago benzinga.com
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and…
1 month ago globenewswire.com
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
-
1 month ago benzinga.com
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene…
1 month ago globenewswire.com
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory…
2 months ago globenewswire.com
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of…
2 months ago thenewswire.com
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec
Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its…
2 months ago thenewswire.com
Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec
Vancouver, British Columbia – TheNewswire - August 18, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to announce that it has entered into a definitive property…
-
2 months ago benzinga.com
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
2 months ago zacks.com
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.
-
2 months ago benzinga.com
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses…
2 months ago globenewswire.com
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth…
2 months ago cnbc.com
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at…
2 months ago prnewswire.com
SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027
New woodsy-themed family area will feature nine attractions, including the Midwest's longest, tallest and fastest suspended family coaster as part of a multi-year transformation MEDIA KIT: Photo,…
2 months ago globenewswire.com
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
3 months ago thenewswire.com
Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project
Achieving Key Regulatory Milestone and Positioning the Company for its Next Phase of Growth Vancouver, British Columbia – TheNewswire - July 28, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC:…
-
3 months ago benzinga.com
CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorderRegulatory milestone enables Company to raise up to $50 million through…
3 months ago globenewswire.com
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics…
4 months ago benzinga.com
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
4 months ago benzinga.com
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $154. See other analysts' views on these stocks.
-
4 months ago benzinga.com
JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9
JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.
-
4 months ago benzinga.com
Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5
Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $6.5.
-
5 months ago benzinga.com
Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses…
-
6 months ago benzinga.com
CAMP4 Therapeutics Submits Reprint To bioRxiv Titled "Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression."
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously…
-
6 months ago benzinga.com
Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.
7 months ago benzinga.com
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names. See complete view of rating changes, including upgrades/downgrades, on our analyst ratings page.
-
7 months ago benzinga.com
Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.
8 months ago benzinga.com
Camp4 Therapeutics Earnings Review: Q4 Summary
Camp4 Therapeutics Earnings Review: Q4 Summary
-
8 months ago benzinga.com
Camp4 Therapeutics Q4 EPS $(0.87) Misses $(0.30) Estimate, Sales $348.000K Miss $538.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.30) by 190 percent. This is a 12.99 percent decrease over losses of…
10 months ago benzinga.com
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
-
10 months ago benzinga.com
UPDATE: CAMP4 Therapeutics Partners With GSK To Develop ASO Therapies For Neurodegenerative And Renal Diseases; Secures $17.5M Upfront
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseasesCAMP4 to receive $17.5 million upfront and…
-
10 months ago benzinga.com
CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each
CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
11 months ago benzinga.com
Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of…